These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 28191684)

  • 1. Sequence of cardiovascular autonomic alterations after fingolimod initiation.
    Simula S; Laitinen TP; Laitinen TM; Hartikainen P; Hartikainen JEK
    Ann Noninvasive Electrocardiol; 2017 Sep; 22(5):. PubMed ID: 28191684
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of fingolimod on cardiac autonomic regulation in patients with multiple sclerosis.
    Simula S; Laitinen T; Laitinen TM; Tarkiainen T; Hartikainen P; Hartikainen JE
    Mult Scler; 2016 Jul; 22(8):1080-5. PubMed ID: 26362903
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Modulation of sphingosine receptors influences circadian pattern of cardiac autonomic regulation.
    Simula S; Laitinen TP; Laitinen TM; Hartikainen P; Hartikainen JE
    Physiol Rep; 2016 Sep; 4(17):. PubMed ID: 27624686
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Central Autonomic Dysfunction Delays Recovery of Fingolimod Induced Heart Rate Slowing.
    Hilz MJ; Intravooth T; Moeller S; Wang R; Lee DH; Koehn J; Linker RA
    PLoS One; 2015; 10(7):e0132139. PubMed ID: 26147106
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Heart rate variability predicts the magnitude of heart rate decrease after fingolimod initiation.
    Simula S; Laitinen TP; Laitinen TM; Hartikainen P; Hartikainen JE
    Mult Scler Relat Disord; 2016 Nov; 10():86-89. PubMed ID: 27919506
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The autonomic balance predicts cardiac responses after the first dose of fingolimod.
    Rossi S; Rocchi C; Studer V; Motta C; Lauretti B; Germani G; Macchiarulo G; Marfia GA; Centonze D
    Mult Scler; 2015 Feb; 21(2):206-16. PubMed ID: 24957049
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 6-Month Effects of Fingolimod on Indexes of Cardiovascular Autonomic Control in Multiple Sclerosis.
    Racca V; Rovaris M; Vaini E; Cavarretta R; Ferratini M; Toccafondi A; Di Rienzo M
    J Am Coll Cardiol; 2016 Nov; 68(18):2027-2029. PubMed ID: 27788858
    [No Abstract]   [Full Text] [Related]  

  • 8. Heart rate variability decreases after 3 months of sustained treatment with fingolimod.
    Vehoff J; Haegele-Link S; Humm A; Kaegi G; Mueller SK; Sauter R; Tettenborn BE; Hundsberger T
    J Neurol; 2017 Nov; 264(11):2313-2317. PubMed ID: 28993873
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of Three Months Fingolimod Therapy on Heart Rate.
    Simula S; Laitinen T; Laitinen TM; Tarkiainen T; Hartikainen JE; Hartikainen P
    J Neuroimmune Pharmacol; 2015 Dec; 10(4):651-4. PubMed ID: 26092537
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cardiac repolarization during fingolimod treatment in patients with relapsing-remitting multiple sclerosis.
    Laiho A; Laitinen TM; Hartikainen P; Hartikainen JEK; Laitinen TP; Simula S
    Brain Behav; 2018 Feb; 8(2):e00925. PubMed ID: 29484274
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cardiovascular autonomic individual profile of relapsing-remitting multiple sclerosis patients and risk of extending cardiac monitoring after first dose fingolimod.
    Vanoli E; Montano N; De Angelis G; Badilini F; Mirabella M; Bonavita S; Patti F; Bianco A; Sparaco M; Chisari C; Laroni A; Frigerio F; Bartezaghi M; Rossi S; Turrini R; Mancardi G
    J Neurol Sci; 2019 Oct; 405():116423. PubMed ID: 31520869
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Acute and long-term effects of fingolimod on heart rhythm and heart rate variability in patients with multiple sclerosis.
    Akbulak RÖ; Rosenkranz SC; Schaeffer BN; Pinnschmidt HO; Willems S; Heesen C; Hoffmann BA
    Mult Scler Relat Disord; 2018 Jan; 19():44-49. PubMed ID: 29127856
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Are there any clinical and electrocardiographic predictors of heart rate reduction in relapsing- remitting multiple sclerosis patients treated with fingolimod?
    Kocyigit D; Yalcin MU; Gurses KM; Tokgozoglu L; Karabudak R
    Mult Scler Relat Disord; 2019 Jan; 27():276-280. PubMed ID: 30447536
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Modulation of Cardiac Autonomic Function by Fingolimod Initiation and Predictors for Fingolimod Induced Bradycardia in Patients with Multiple Sclerosis.
    Li K; Konofalska U; Akgün K; Reimann M; Rüdiger H; Haase R; Ziemssen T
    Front Neurosci; 2017; 11():540. PubMed ID: 29075174
    [No Abstract]   [Full Text] [Related]  

  • 15. The management and outcomes of fingolimod first dose cardiac monitoring in UK patients with relapsing-remitting multiple sclerosis.
    Datt J; Baldock L; Pull E; Webber B
    Mult Scler Relat Disord; 2016 Jan; 5():40-6. PubMed ID: 26856942
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fingolimod initiation in multiple sclerosis patients is associated with potential beneficial cardiovascular autonomic effects.
    Hilz MJ; Wang R; de Rojas Leal C; Liu M; Canavese F; Roy S; Hösl KM; Winder K; Lee DH; Linker RA
    Ther Adv Neurol Disord; 2017 Apr; 10(4):191-209. PubMed ID: 28507603
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Update on the cardiovascular profile of fingolimod in the therapy of relapsing-remitting multiple sclerosis (MS).
    Meissner A; Limmroth V
    Mult Scler Relat Disord; 2016 Jul; 8():19-26. PubMed ID: 27456870
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fingolimod first-dose effects in patients with relapsing multiple sclerosis concomitantly receiving selective serotonin-reuptake inhibitors.
    Bermel RA; Hashmonay R; Meng X; Randhawa S; von Rosenstiel P; Sfikas N; Kantor D
    Mult Scler Relat Disord; 2015 May; 4(3):273-80. PubMed ID: 26008945
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Real-World Safety and Patient Profile of Fingolimod in Relapsing-Remitting Multiple Sclerosis: A Prospective Analysis in Buenos Aires, Argentina.
    Rojas JI; Patrucco L; Miguez J; Cristiano E
    Clin Neuropharmacol; 2017; 40(6):251-254. PubMed ID: 28976408
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fingolimod for relapsing-remitting multiple sclerosis.
    La Mantia L; Tramacere I; Firwana B; Pacchetti I; Palumbo R; Filippini G
    Cochrane Database Syst Rev; 2016 Apr; 4(4):CD009371. PubMed ID: 27091121
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.